Locations:
Search
Rebound risk is shaped by patient characteristics and mechanism of action of current DMT
First-of-kind prediction model demonstrates high consistency across internal and external validation
Real-world study also finds no significant rise in ocrelizumab-related risk with advanced age
The disease is not a barrier to pregnancy, but risks from disease-modifying therapies must be managed
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Risk of new MS activity is small in those older than 55 with stable disease who stop MS therapy
$1.1M award expands follow-up to six years with focus on clinical endpoints
Relapse rates were lower with oral or infusion therapy after initial injectable DMT
Observational studies comparing disease-modifying therapies can help guide clinical decisions
Unlikely to be severe, infections are associated with anti-CD20 therapies and fingolimod
Observational study suggests age may be a better guide than disease stability
Advertisement
Advertisement